Bank analyst on Novo Nordisk report: Impressive quarter, to say the least
Novo Nordisk has beaten expectations in terms of both its GLP drugs and its obesity treatment, and according to senior equity analyst at Sydbank Søren Løntoft Hansen, the report which Denmark's largest pharmaceutical company sent out Wednesday afternoon is highly impressive.
.jpg)
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
The Q2 report that Novo Nordisk introduced on Wednesday afternoon is impressive, to say the least.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance for the rest of the year
For subscribers
.jpg)
.jpg)
Eli Lilly specifies guidance for this year's revenue
For subscribers
